New research identifies distinct urinary metabolites linked to bladder cancer and recurrence, raising hope for non-invasive ...

Dr Thomas Flaig from the University of Colorado Anschutz discusses a paradigm shift in treating urothelial carcinoma patients ...

New urinary biomarkers show promise for bladder cancer detection and recurrence prediction. Learn more about this non-invasive diagnostic approach.

The Centers for Medicare & Medicaid Services has issued a permanent billing and reimbursement J-code, J9183, for the ...

Two years ago, the Emerald-1 trial hit its primary endpoint, showing that a cocktail of Imfinzi, Avastin and TACE reduced the ...

Probability of Remaining Event-Free at 24 Months by Kaplan-Meier Analysis After Achieving Complete Response at Three Months ...

Conditional approval of intravesical gene therapy was supported by clinical evidence showing a 53.4% complete response rate in patients with treatment-resistant non-muscle-invasive bladder cancer.

Treating early-stage prostate cancer was one thing, but Henard’s doctor at the small rural hospital nearby told him the new diagnosis called for a meticulous, highly sophisticated form of treatment.

ImmunityBio Inc. shares are down during Thursday’s premarket session. Year to date, the stock has jumped over 300%. The ...

Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFO Tel: +44 (0)29 2048 0180 The Company’s lead development ...

Adstiladrin may now be thawed in a water bath following an FDA label update, facilitating more efficient treatment delivery for bladder cancer.

Diagnostic test based on urinary tumor markers hold promise for earlier or prompt detection of bladder cancer in patients ...